



Liste modèle des médicaments essentiels

Medicines for COVID-19

Section	Indications
Medicines for COVID-19 Refer to WHO living guidelines	COVID-19

Abacavir

Section	Indications
Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors Oral > Solid: 300 mg tablet (as sulfate)	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Abacavir + lamivudine

Section	Indications
Fixed-dose combinations of antiretrovirals Oral > Solid: 120 mg (as sulfate) + 60 mg tablet (dispersible, scored)	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Abacavir + lamivudine + lopinavir + ritonavir

Section	Indications
Fixed-dose combinations of antiretrovirals Oral > Solid: 30 mg + 15 mg + 40 mg + 10 mg capsule containing oral granules	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Aciclovir

Section	Indications
Antiherpes medicines Parenteral > General injections > IV: 250 mg in vial powder for injection (as sodium salt) Oral > Liquid: 200 mg per 5 mL Oral > Solid: 200 mg tablet	Zoster Varicella Herpes simplex infections

Albendazole

Section	Indications
Intestinal anthelminthics Oral > Solid > tablet: 400 mg (chewable, scored)	Echinococcosis Enterobiasis Trichuriasis Hookworm diseases Cysticercosis Ascariasis
Cysticidal medicines Oral > Solid > tablet: 400 mg (chewable, scored); 200 mg (chewable)	Other specified echinococcosis Cysticercosis of central nervous system
Antifilarials Oral > Solid > tablet: 400 mg (chewable, scored)	Lymphatic filariasis

Amikacin

Section	Indications
Antituberculosis medicines Parenteral > General injections > unspecified: 250 mg per mL in 2 mL vial (as sulfate)	Multi-drug resistant Mycobacterium tuberculosis
Access group antibiotics Parenteral > General injections > unspecified: 250 mg per mL in 2 mL vial (as sulfate); 50 mg per mL in 2 mL vial (as sulfate)	Premier choix Neutropenia (high-risk) co-prescrite avec cefotaxime Inflammatory and other diseases of prostate (severe) co-prescrite avec cefotaxime Acute pyelonephritis (severe) co-prescrite avec ceftriaxone Inflammatory and other diseases of prostate (severe) co-prescrite avec ceftriaxone Acute pyelonephritis (severe)
Parenteral > General injections > unspecified: 250 mg per mL in 2 mL vial (as sulfate)	Second choix co-prescrite avec cloxacillin Sepsis without septic shock

Amodiaquine

Section	Indications
Antimalarial medicines > For curative treatment Oral > Solid: 153 mg (as hydrochloride); 200 mg (as hydrochloride)	Malaria due to <i>Plasmodium falciparum</i> Malaria due to <i>Plasmodium vivax</i>

Amodiaquine + sulfadoxine + pyrimethamine

Section	Indications
Antimalarial medicines > For chemoprevention Oral > Solid: 76.5 mg (as hydrochloride) [3] + 250 mg + 12.5 mg [1] dispersible tablets in co-package; 153 mg (as hydrochloride) [3] + 500 mg + 25 mg [1] dispersible tablets in co-package	Malaria

Amoxicillin

Section	Indications
Access group antibiotics	Premier choix
Oral > Liquid: 125 mg per 5 mL (as trihydrate) powder for oral liquid; 250 mg per 5 mL (as trihydrate) powder for oral liquid	Bacterial pneumonia (Community-acquired pneumonia - mild to moderate)
Parenteral > General injections > unspecified: 250 mg in vial (as sodium) powder for injection; 500 mg in vial (as sodium) powder for injection; 1 g in vial (as sodium) powder for injection	Acute malnutrition in infants, children or adolescents (uncomplicated) [children]
Oral > Solid > dispersible tablet: 250 mg (scored) (as trihydrate); 500 mg (scored) (as trihydrate)	Acute malnutrition in infants, children or adolescents (complicated) [children]
Oral > Solid > dosage form: 250 mg (as trihydrate); 500 mg (as trihydrate)	Acute pharyngitis
Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral liquid; 250 mg per 5 mL (anhydrous) powder for oral liquid	Chronic obstructive pulmonary disease with acute exacerbation
Oral > Solid > dosage form: 250 mg (as trihydrate); 500 mg (as trihydrate); 1 g (as trihydrate)	Periapical abscess without sinus
	Acute otitis media
	Acute sinusitis
	co-prescrite avec gentamicin
	Bacterial pneumonia (Community-acquired pneumonia - severe) [children]
	co-prescrite avec gentamicin
	Sepsis without septic shock
	Second choix
	Bacterial meningitis
	Autres indications
	Infectious cystitis
	Bacterial infection of unspecified site

Amoxicillin + clavulanic acid

Section	Indications
Access group antibiotics Parenteral > General injections > IV: 500 mg (as sodium salt) + 100 mg (as potassium salt) powder for injection; 1000 mg (as sodium salt) + 200 mg (as potassium salt) powder for injection Oral > Liquid: 125 mg (as trihydrate) + 31.25 mg (as potassium salt) / 5 mL powder for oral liquid; 250 mg (as trihydrate) + 62.5 mg (as potassium salt) / 5 mL powder for oral liquid Oral > Solid > dispersible tablet: 200 mg (as trihydrate) + 28.5 mg (as potassium salt); 250 mg (as trihydrate) + 62.5 mg (as potassium salt) Oral > Solid > tablet: 500 mg (as trihydrate) + 125 mg (as potassium salt); 875 mg (as trihydrate) + 125 mg (as potassium salt) Oral > Solid > tablet: 500 mg (as trihydrate) + 125 mg (as potassium salt)	Premier choix Peritoneal abscess (mild-moderate) Neutropenia (low-risk) Other specified pneumonia (Hospital-acquired pneumonia) Infectious cystitis Chronic obstructive pulmonary disease with acute exacerbation Peritonitis (mild-moderate) Acute sinusitis Bacterial cellulitis, erysipelas or lymphangitis Bacterial pneumonia (Community-acquired pneumonia - severe) [children] Second choix Osteomyelitis or osteitis Acute otitis media Other specified prophylactic measures Bacterial infection of joint Bacterial pneumonia (Community-acquired pneumonia - mild to moderate) co-prescrite avec clarithromycin Bacterial pneumonia (Community-acquired pneumonia - severe)
Antituberculosis medicines Oral > Liquid: 250 mg (as trihydrate) + 62.5 mg (as potassium salt) / 5 mL powder for oral liquid Oral > Solid > tablet: 500 mg (as trihydrate) + 125 mg (as potassium salt)	Autres indications Bacterial infection of unspecified site Multi-drug resistant Mycobacterium tuberculosis

Amphotericin B

Section	Indications
<p>Antifungal medicines</p> <p>Parenteral > General injections > IV: 50 mg in vial powder for injection (liposomal complex); 50 mg in vial powder for injection (as sodium deoxycholate)</p>	<p>Blastomycosis</p> <p>Cryptococcosis</p> <p>Candidosis</p> <p>Coccidioidomycosis</p> <p>Histoplasmosis</p> <p>Sporotrichosis</p> <p>Aspergillosis</p>
<p>Antileishmaniasis medicines</p> <p>Parenteral > General injections > IV: 50 mg in vial powder for injection (liposomal complex); 50 mg in vial powder for injection (as sodium deoxycholate)</p>	<p>Visceral leishmaniasis</p>

Ampicillin

Section	Indications
<p>Access group antibiotics</p> <p>Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection; 1 g in vial (as sodium salt) powder for injection</p> <p>Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral suspension</p> <p>Oral > Solid: 250 mg (anhydrous); 500 mg (anhydrous)</p>	<p>Premier choix</p> <p>co-prescrite avec gentamicin</p> <p>Peritoneal abscess (severe)</p> <p>co-prescrite avec gentamicin</p> <p>Sepsis without septic shock</p> <p>co-prescrite avec gentamicin</p> <p>Peritoneal abscess (mild-moderate)</p> <p>co-prescrite avec gentamicin</p> <p>Peritonitis (severe)</p> <p>co-prescrite avec gentamicin</p> <p>Acute malnutrition in infants, children or adolescents (complicated) [children]</p> <p>co-prescrite avec gentamicin</p> <p>Peritonitis (mild-moderate)</p> <p>co-prescrite avec gentamicin</p> <p>Bacterial pneumonia (Community-acquired pneumonia - severe) [children]</p> <p>Second choix</p> <p>Bacterial meningitis</p> <p>Autres indications</p> <p>Bacterial infection of unspecified site</p>

Anidulafungin

Section	Indications
Antifungal medicines	Therapeutic equivalent to micafungin pour Systemic or invasive candidosis

Ansuvimab

Section	Indications
Medicines for Ebola virus disease Parenteral > General injections > IV: 400 mg powder for injection	Ebola virus disease

Artemether

Section	Indications
Antimalarial medicines > For curative treatment Parenteral > General injections > IM: 80 mg per mL in 1 mL ampoule (oily injection)	Malaria due to Plasmodium falciparum Malaria due to Plasmodium vivax

Artemether + lumefantrine

Section	Indications
Antimalarial medicines > For curative treatment Oral > Solid: 20 mg + 120 mg tablet; 20 mg + 120 mg dispersible tablet	Malaria due to Plasmodium falciparum Malaria due to Plasmodium vivax

Artesunate

Section	Indications
Antimalarial medicines > For curative treatment Parenteral > General injections > IV: 60 mg in ampoule containing anhydrous artesunic acid with a separate ampoule of 5% sodium bicarbonate solution Oral > Solid: 50 mg tablet Local > Rectal > Other: 50 mg capsules; 200 mg capsules; 100 mg capsules	Malaria due to Plasmodium falciparum Malaria due to Plasmodium vivax

Artesunate + amodiaquine

Section	Indications
Antimalarial medicines > For curative treatment Oral > Solid: 25 mg + 67.5 mg tablet; 50 mg + 135 mg tablet; 100 mg + 270 mg tablet	Malaria due to Plasmodium falciparum Malaria due to Plasmodium vivax

Artesunate + mefloquine

Section	Indications
Antimalarial medicines > For curative treatment Oral > Solid: 25 mg + 55 mg tablet; 100 mg + 220 mg tablet	Malaria due to Plasmodium falciparum Malaria due to Plasmodium vivax

Artesunate + pyronaridine tetraphosphate

Section	Indications
Antimalarial medicines > For curative treatment Oral > Solid: 60 mg + 180 mg tablet; 20 mg + 60 mg granules	Malaria due to Plasmodium falciparum Malaria due to Plasmodium vivax

Atazanavir

Section	Indications
Antiretrovirals > Protease inhibitors Oral > Solid: 100 mg (as sulfate); 300 mg (as sulfate)	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Atazanavir + ritonavir

Section	Indications
Antiretrovirals > Protease inhibitors Oral > Solid: 300 mg (as sulfate) + 100 mg tablet (heat stable)	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Atoltivimab + maftivimab + odesivimab

Section	Indications
Medicines for Ebola virus disease Parenteral > General injections > IV: 241.7 mg + 241.7 mg + 241.7 mg in 14.5 mL vial	Ebola virus disease

Azithromycin

Section	Indications
<p>Watch group antibiotics</p> <p>Oral > Liquid: 200 mg per 5 mL (anhydrous) powder for oral liquid</p> <p>Oral > Solid > dosage form: 250 mg (anhydrous); 500 mg (anhydrous)</p>	<p>Premier choix</p> <ul style="list-style-type: none">Chlamydia trachomatisTyphoid feverYawsParatyphoid feverCholeraCholera [children]Trachoma <p>co-prescrite avec ceftriaxone</p> <ul style="list-style-type: none">Gonococcal infection <p>Second choix</p> <ul style="list-style-type: none">Infectious gastroenteritis or colitis without specification of infectious agent <p>co-prescrite avec cefixime</p> <ul style="list-style-type: none">Gonococcal infection

Aztreonam

Section	Indications
<p>Reserve group antibiotics</p> <p>Parenteral > General injections > unspecified: 1 g in vial powder for injection; 2 g in vial powder for injection</p>	<ul style="list-style-type: none">Other specified bacterial diseases

Bedaquiline

Section	Indications
<p>Antituberculosis medicines</p> <p>Oral > Solid: 100 mg tablet; 20 mg tablet</p>	<ul style="list-style-type: none">Multi-drug resistant Mycobacterium tuberculosis

Benzathine benzylpenicillin

Section	Indications
<p>Access group antibiotics</p> <p>Parenteral > General injections > IM: 1.2 million IU in vial (\approx 900 mg) powder for injection; 2.4 million IU in vial (\approx 1.8 g) powder for injection</p>	<p>Premier choix</p> <ul style="list-style-type: none">SyphilisCongenital syphilis [children] <p>Autres indications</p> <ul style="list-style-type: none">Bacterial infection of unspecified site

Benznidazole

Section	Indications
American trypanosomiasis Oral > Solid > tablet: 100 mg (scored); 50 mg (scored); 12.5 mg	Chagas disease

Benzylpenicillin

Section	Indications
Access group antibiotics	Premier choix
Parenteral > General injections > unspecified: 600 mg in vial powder for injection (=1 million IU as sodium or potassium salt); 3 g in vial powder for injection (=5 million IU as sodium or potassium salt)	Congenital syphilis [children]
Parenteral > General injections > unspecified: 600 mg in vial powder for injection (= 1 million IU as sodium or potassium salt); 3 g in vial powder for injection (= 5 million IU as sodium or potassium salt)	Syphilis
	co-prescrite avec gentamicin
	Sepsis without septic shock
	co-prescrite avec gentamicin
	Acute malnutrition in infants, children or adolescents (complicated) [children]
	co-prescrite avec gentamicin
	Bacterial pneumonia (Community-acquired pneumonia - severe) [children]
	Second choix
	Bacterial meningitis
	Autres indications
	Bacterial infection of unspecified site

Capreomycin

Section	Indications
Antituberculosis medicines	Multi-drug resistant Mycobacterium tuberculosis

Caspofungin

Section	Indications
Antifungal medicines	Therapeutic equivalent to micafungin pour Systemic or invasive candidosis

Cefalexin

Section	Indications
<p>Access group antibiotics</p> <p>Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral liquid; 250 mg per 5 mL (anhydrous) powder for oral liquid</p> <p>Oral > Solid: 250 mg (as monohydrate)</p> <p>Oral > Solid: 250 mg (as monohydrate); 500 mg (as monohydrate)</p> <p>Oral > Solid > dispersible tablet: 125 mg; 250 mg</p>	<p>Premier choix</p> <p>Bacterial cellulitis, erysipelas or lymphangitis</p> <p>Second choix</p> <p>Acute pharyngitis</p> <p>Chronic obstructive pulmonary disease with acute exacerbation</p> <p>Autres indications</p> <p>Bacterial infection of unspecified site</p>

Cefazolin

Section	Indications
<p>Access group antibiotics</p> <p>Parenteral > General injections > unspecified: 1 g in vial (as sodium salt) powder for injection</p>	<p>Premier choix</p> <p>Other specified prophylactic measures</p> <p>co-prescrite avec metronidazole</p> <p>Other specified prophylactic measures</p> <p>Second choix</p> <p>Osteomyelitis or osteitis</p> <p>Bacterial infection of joint</p> <p>Autres indications</p> <p>Surgical site infection</p>

Cefepime

Section	Indications
<p>Watch group antibiotics</p> <p>Parenteral > General injections > unspecified: 500 mg in vial (as hydrochloride) powder for injection; 1 g in vial (as hydrochloride) powder for injection; 2 g in vial (as hydrochloride) powder for injection</p>	<p>Other specified bacterial diseases</p>

Cefiderocol

Section	Indications
<p>Reserve group antibiotics</p> <p>Parenteral > General injections > IV: 1 g in vial (as sulfate tosylate) powder for injection</p>	<p>Carbapenem-resistant Pseudomonas aeruginosa</p> <p>Carbapenem resistant Enterobacteriales</p>

Cefixime

Section

Watch group antibiotics

Oral > Liquid: 100 mg per 5 mL powder for oral liquid

Oral > Solid: 200 mg (as trihydrate); 400 mg (as trihydrate)

Indications

Second choix

Infectious gastroenteritis or colitis without specification of infectious agent

co-prescrite avec azithromycin

Gonococcal infection

Cefotaxime

Section	Indications
Watch group antibiotics Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt)	Premier choix Other specified pneumonia (Hospital-acquired pneumonia) Bacterial meningitis Bacterial pneumonia (Community-acquired pneumonia - severe) [children] co-prescrite avec amikacin Inflammatory and other diseases of prostate (severe) co-prescrite avec amikacin Acute pyelonephritis (severe) co-prescrite avec clarithromycin Bacterial pneumonia (Community-acquired pneumonia - severe) co-prescrite avec metronidazole Peritonitis (severe) co-prescrite avec metronidazole Peritonitis (mild-moderate) co-prescrite avec metronidazole Peritoneal abscess (severe) co-prescrite avec metronidazole Peritoneal abscess (mild-moderate)
	Second choix Osteomyelitis or osteitis Bacterial infection of joint Inflammatory and other diseases of prostate (mild to moderate) Acute pyelonephritis (mild to moderate) Sepsis without septic shock
	Autres indications Bacterial infection of unspecified site

Ceftaroline

Section	Indications
Reserve group antibiotics Parenteral > General injections > IV: 400 mg in vial (as fosamil) powder for injection; 600 mg in vial (as fosamil) powder for injection	Other specified bacterial diseases

Ceftazidime

Section	Indications
<p>Watch group antibiotics</p> <p>Parenteral > General injections > unspecified: 250 mg in vial (as pentahydrate) powder for injection; 1 g in vial (as pentahydrate) powder for injection</p>	<p>Premier choix</p> <p>co-prescrite avec vancomycin</p> <p>Endophthalmitis</p> <p>Autres indications</p> <p>Pseudomonas aeruginosa resistant to other antibiotic</p>

Ceftazidime + avibactam

Section	Indications
<p>Reserve group antibiotics</p> <p>Parenteral > General injections > IV: 2 g in vial + 0.5 g in vial powder for injection</p>	<p>Carbapenem-resistant Pseudomonas aeruginosa</p> <p>Carbapenem resistant Enterobacteriales</p>

Ceftolozane + tazobactam

Section	Indications
<p>Reserve group antibiotics</p> <p>Parenteral > General injections > IV: 1 g + 0.5 g powder for injection</p>	<p>Carbapenem-resistant Pseudomonas aeruginosa</p>

Ceftriaxone

Section	Indications
<p>Watch group antibiotics</p> <p>Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt)</p> <p>Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)</p> <p>Parenteral > Locoregional injections > Intravitreal: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)</p> <p>Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt)</p> <p>Parenteral > General injections > unspecified: 2 g in vial; 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt)</p>	<p>Premier choix</p> <p>Typhoid fever</p> <p>Bacterial pneumonia (Community-acquired pneumonia - severe) [children]</p> <p>Paratyphoid fever</p> <p>Other specified pneumonia (Hospital-acquired pneumonia)</p> <p>Bacterial meningitis</p> <p>co-prescrite avec amikacin</p> <p>Acute pyelonephritis (severe)</p> <p>co-prescrite avec amikacin</p> <p>Inflammatory and other diseases of prostate (severe)</p> <p>co-prescrite avec azithromycin</p> <p>Gonococcal infection</p> <p>co-prescrite avec clarithromycin</p> <p>Bacterial pneumonia (Community-acquired pneumonia - severe)</p>

co-prescrite avec metronidazole

Necrotising fasciitis

co-prescrite avec metronidazole

Peritonitis (mild-moderate)

co-prescrite avec metronidazole

Peritonitis (severe)

co-prescrite avec metronidazole

Peritoneal abscess (mild-moderate)

co-prescrite avec metronidazole

Peritoneal abscess (severe)

co-prescrite avec vancomycin

Endophthalmitis

Second choix

Bacterial infection of joint

Osteomyelitis or osteitis

Infectious gastroenteritis or colitis without specification of infectious agent

Sepsis without septic shock

Inflammatory and other diseases of prostate (mild to moderate)

Acute pyelonephritis (mild to moderate)

Autres indications

Bacterial infection of unspecified site

Cefuroxime

Section

Watch group antibiotics

Parenteral > General injections > IV: 250 mg in vial (as sodium salt)
powder for injection; 750 mg in vial (as sodium salt) powder for injection;
1.5 g in vial (as sodium salt) powder for injection

Indications

Second choix

Other specified prophylactic measures

Chloramphenicol

Section	Indications
<p>Access group antibiotics</p> <p>Parenteral > General injections > IV: 1 g in vial powder for injection (sodium succinate)</p> <p>Parenteral > General injections > IM: 500 mg in 2 mL ampoule oily suspension for injection</p> <p>Oral > Liquid: 150 mg per 5 mL (as palmitate)</p> <p>Oral > Solid: 250 mg capsule</p>	<p>Second choix</p> <p>Bacterial meningitis</p> <p>Autres indications</p> <p>Bacterial infection of unspecified site</p>

Chloroquine

Section	Indications
<p>Antimalarial medicines > For chemoprevention</p> <p>Oral > Liquid: 50 mg per 5 mL syrup (as phosphate or sulfate)</p> <p>Oral > Solid: 150 mg tablet (as phosphate or sulfate)</p> <p>Antimalarial medicines > For curative treatment</p> <p>Parenteral > General injections > IV: 40 mg per mL in 5 mL ampoule (as hydrochloride, phosphate or sulfate)</p> <p>Oral > Liquid: 50 mg per 5 mL syrup (as phosphate or sulfate)</p> <p>Oral > Solid: 150 mg tablet (as phosphate or sulfate); 100 mg tablet (as phosphate or sulfate)</p>	<p>Malaria due to Plasmodium falciparum</p> <p>Malaria due to Plasmodium vivax</p> <p>Malaria due to Plasmodium ovale</p> <p>Malaria due to Plasmodium malariae</p> <p>Malaria due to Plasmodium falciparum</p> <p>Malaria due to Plasmodium vivax</p>

Ciprofloxacin

Section

Watch group antibiotics

Parenteral > General injections > IV: 2 mg per mL (as hydrate)
Oral > Liquid: 250 mg per 5 mL (anhydrous)
Oral > Solid: 250 mg (as hydrochloride)
Oral > Solid > dosage form: 250 mg (as hydrochloride); 500 mg (as hydrochloride); 100 mg (as hydrochloride)
Oral > Solid > dosage form: 250 mg (as hydrochloride); 500 mg (as hydrochloride)

Indications

Premier choix

Neutropenia (low-risk)

Inflammatory and other diseases of prostate (mild to moderate)

Typhoid fever

Paratyphoid fever

Infectious gastroenteritis or colitis without specification of infectious agent

Acute pyelonephritis (mild to moderate)

Second choix

Cholera

Cholera [children]

co-prescrite avec metronidazole

Peritoneal abscess (mild-moderate)

co-prescrite avec metronidazole

Peritonitis (mild-moderate)

Autres indications

Bacterial infection of unspecified site

Clarithromycin

Section

Watch group antibiotics

Oral > Liquid: 125 mg per 5 mL powder for oral liquid; 250 mg per 5 mL powder for oral liquid

Parenteral > General injections > unspecified: 500 mg in vial powder for injection

Oral > Solid > dosage form: 500 mg; 250 mg

Oral > Solid > dosage form: 500 mg

Indications

Premier choix

co-prescrite avec cefotaxime

Bacterial pneumonia (Community-acquired pneumonia - severe)

co-prescrite avec ceftriaxone

Bacterial pneumonia (Community-acquired pneumonia - severe)

Second choix

Acute pharyngitis

co-prescrite avec amoxicillin + clavulanic acid

Bacterial pneumonia (Community-acquired pneumonia - severe)

Autres indications

Helicobacter pylori associated gastric ulcer

Clindamycin

Section	Indications
<p>Access group antibiotics</p> <p>Oral > Liquid: 75 mg per 5 mL (as palmitate hydrochloride)</p> <p>Oral > Solid: 150 mg (as hydrochloride) capsule</p> <p>Parenteral > General injections > unspecified: 150 mg per mL (as phosphate) injection</p> <p>Parenteral > General injections > IV: 150 mg per mL (as phosphate); 600 mg per 4 mL (as phosphate); 900 mg per 6 mL (as phosphate)</p> <p>Oral > Liquid: 75 mg per 5 mL powder for oral liquid (as palmitate hydrochloride)</p> <p>Oral > Solid: 150 mg (as hydrochloride)</p>	<p>Premier choix co-prescrite avec piperacillin + tazobactam</p> <p>Necrotising fasciitis</p> <p>Second choix</p> <p>Osteomyelitis or osteitis</p> <p>Bacterial infection of joint</p> <p>Autres indications</p> <p>Bacterial infection of unspecified site</p>

Clofazimine

Section	Indications
<p>Antituberculosis medicines</p> <p>Oral > Solid: 100 mg; 50 mg</p>	<p>Multi-drug resistant Mycobacterium tuberculosis</p>
<p>Antileprosy medicines</p> <p>Oral > Solid: 100 mg; 50 mg</p>	<p>Leprosy</p>

Clotrimazole

Section	Indications
<p>Antifungal medicines</p> <p>Local > Topical > Other: 1% vaginal cream; 10% vaginal cream; 100 mg vaginal tablet; 500 mg vaginal tablet</p>	<p>Vulvovaginal candidosis</p>

Cloxacillin

Section	Indications
<p>Access group antibiotics</p> <p>Oral > Liquid: 125 mg per 5 mL (as sodium salt) powder for oral liquid</p> <p>Oral > Solid: 500 mg (as sodium salt) capsule; 1 g (as sodium salt) capsule</p> <p>Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection</p> <p>Oral > Liquid: 125 mg per 5 mL (as sodium salt) powder for oral liquid; 250 mg per 5 mL (as sodium salt) powder for oral liquid</p> <p>Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection; 250 mg in vial (as sodium salt) powder for injection</p> <p>Oral > Solid > capsule: 500 mg (as sodium salt); 1 g (as sodium salt); 250 mg (as sodium salt)</p>	<p>Premier choix</p> <p>Bacterial infection of joint</p> <p>Osteomyelitis or osteitis</p> <p>Bacterial cellulitis, erysipelas or lymphangitis</p> <p>Second choix</p> <p>co-prescrite avec amikacin</p> <p>Sepsis without septic shock</p> <p>Autres indications</p> <p>Bacterial infection of unspecified site</p>

Cobicistat + elvitegravir + emtricitabine + tenofovir disoproxil fumarate

Section	Indications
<p>Fixed-dose combinations of antiretrovirals</p> <p>Oral > Solid: 150 mg + 150 mg + 200 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)</p>	<p>Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified</p>

Cobicistat + elvitegravir + emtricitabine+ tenofovir alafenamide

Section	Indications
<p>Fixed-dose combinations of antiretrovirals</p> <p>Oral > Solid: 150 mg + 150 mg + 200 mg + 10 mg</p>	<p>Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified</p>

Colistin (injection)

Section	Indications
<p>Reserve group antibiotics</p> <p>Parenteral > General injections > unspecified: 1 million IU in vial (as colistemethate sodium)</p> <p>Parenteral > General injections > unspecified: 1 million IU in vial (as colistemethate sodium) (equivalent to 34 mg colistin base activity)</p>	<p>Other specified bacterial diseases</p> <p>Carbapenem resistant Acinetobacter baumannii</p> <p>Carbapenem-resistant Pseudomonas aeruginosa</p> <p>Carbapenem resistant Enterobacterales</p>

Cycloserine

Section	Indications
Antituberculosis medicines Oral > Solid: 250 mg; 125 mg	Multi-drug resistant Mycobacterium tuberculosis

Daclatasvir

Section	Indications
Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations Oral > Solid > tablet: 30 mg (as hydrochloride); 60 mg (as hydrochloride)	Chronic hepatitis C

Daclatasvir + sofosbuvir

Section	Indications
Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations Oral > Solid > tablet: 60 mg + 400 mg	Chronic hepatitis C

Dapsone

Section	Indications
Antileprosy medicines Oral > Solid: 100 mg tablet; 50 mg tablet; 25 mg tablet	Leprosy

Daptomycin

Section	Indications
Reserve group antibiotics Parenteral > General injections > IV: 350 mg in vial powder for injection; 500 mg in vial powder for injection	Other specified bacterial diseases

Darunavir

Section	Indications
Antiretrovirals > Protease inhibitors Oral > Solid: 75 mg; 400 mg; 600 mg; 800 mg	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Dasabuvir

Section	Indications
Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations Oral > Solid: 250 mg tablet	Chronic hepatitis C

Delafloxacin

Section	Indications
Watch group antibiotics Parenteral > General injections > IV: 300 mg lyophilized powder for injection Oral > Solid: 450 mg	Methicillin resistant <i>Staphylococcus aureus</i>

Delamanid

Section	Indications
Antituberculosis medicines Oral > Solid > dispersible tablet: 25 mg Oral > Solid > tablet: 50 mg	Multi-drug resistant <i>Mycobacterium tuberculosis</i>

Didanosine

Section	Indications
Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors Oral > Liquid: 100 mg buffered powder for oral solution; 167 mg buffered powder for oral solution; 250 mg buffered powder for oral solution Oral > Solid: 25 mg buffered chewable dispersible tablet; 50 mg buffered chewable dispersible tablet; 100 mg buffered chewable dispersible tablet; 150 mg buffered chewable dispersible tablet; 200 mg buffered chewable dispersible tablet; 125 mg unbuffered enteric coated capsule; 200 mg unbuffered enteric coated capsule; 250 mg unbuffered enteric coated capsule; 400 mg unbuffered enteric coated capsule	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Diethylcarbamazine

Section	Indications
Antifilarials Oral > Solid: 50 mg tablet (dihydrogen citrate); 100 mg tablet (dihydrogen citrate)	Lymphatic filariasis

Dihydroartemisinin + piperaquine phosphate

Section	Indications
Antimalarial medicines > For curative treatment Oral > Solid: 40 mg + 320 mg tablet; 20 mg + 160 mg tablet	Malaria due to <i>Plasmodium falciparum</i> Malaria due to <i>Plasmodium vivax</i>

Diloxanide

Section	Indications
Antiamoebic and antigiardiasis medicines Oral > Solid: 500 mg (furoate)	Amoebiasis

Dolutegravir

Section	Indications
Antiretrovirals > Integrase inhibitors Oral > Solid: 50 mg tablet; 10 mg tablet (dispersible, scored)	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Dolutegravir + lamivudine + tenofovir

Section	Indications
Fixed-dose combinations of antiretrovirals Oral > Solid: 50 mg + 300 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Doxycycline

Section	Indications
Access group antibiotics	Premier choix
Oral > Liquid: 25 mg per 5 mL (anhydrous); 50 mg per 5 mL (anhydrous)	Chlamydia trachomatis
Oral > Solid: 100 mg (as hyclate); 50 mg (as hyclate)	Cholera
Parenteral > General injections > unspecified: 100 mg in vial powder for injection	Second choix
Oral > Liquid: 25 mg per 5 mL powder for oral liquid (monohydrate); 50 mg per 5 mL (calcium)	Bacterial pneumonia (Community-acquired pneumonia - mild to moderate)
Oral > Solid > dispersible tablet: 100 mg (as monohydrate)	Chronic obstructive pulmonary disease with acute exacerbation
Oral > Solid > dosage form: 50 mg (as hyclate); 100 mg (as hyclate)	Cholera [children]
Oral > Solid > dosage form: 100 mg (as hyclate)	Autres indications
Antimalarial medicines > For curative treatment	Bacterial infection of unspecified site
Oral > Solid: 100 mg (hydrochloride or hyclate); 100 mg dispersible tablet (as monohydrate)	Malaria due to Plasmodium falciparum
Antimalarial medicines > For chemoprevention	Malaria due to Plasmodium falciparum
Oral > Solid: 100 mg (hydrochloride or hyclate)	

Efavirenz

Section	Indications
Antiretrovirals > Non-nucleoside reverse transcriptase inhibitors Oral > Solid: 600 mg tablet	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Efavirenz + emtricitabine + tenofovir

Section	Indications
Fixed-dose combinations of antiretrovirals Oral > Solid: 600 mg + 200 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Efavirenz + lamivudine + tenofovir

Section	Indications
Fixed-dose combinations of antiretrovirals Oral > Solid: 400 mg + 300 mg + 300 mg (tenofovir disoproxil fumarate, equivalent to 245 mg tenofovir disoproxil)	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified Therapeutic equivalent to efavirenz + emtricitabine + tenofovir pour Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Eflornithine

Section	Indications
Medicines for the treatment of 2nd stage African trypanosomiasis Parenteral > General injections > IV: 200 mg per mL in 50 mL bottle (hydrochloride)	African trypanosomiasis

Elbasvir + grazoprevir

Section	Indications
Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations Oral > Solid: 50 mg + 100 mg	Chronic hepatitis C

Emtricitabine

Section	Indications
Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors Oral > Liquid: 10 mg per mL Oral > Solid: 200 mg	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Emtricitabine + rilpivirine + tenofovir alafenamide

Section	Indications
Fixed-dose combinations of antiretrovirals Oral > Solid: 200 mg + 25 mg + 25 mg	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Emtricitabine + rilpivirine + tenofovir disoproxil fumarate

Section	Indications
Fixed-dose combinations of antiretrovirals Oral > Solid: 200 mg + 25 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Emtricitabine + tenofovir

Section	Indications
Fixed-dose combinations of antiretrovirals Oral > Solid: 200 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified Contact with or exposure to human immunodeficiency virus

Emtricitabine + tenofovir alafenamide

Section	Indications
Fixed-dose combinations of antiretrovirals Oral > Solid: 200 mg + 10 mg; 200 mg + 25 mg	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Entecavir

Section	Indications
Medicines for hepatitis B > Nucleoside/Nucleotide reverse transcriptase inhibitors Oral > Liquid: 0.05 mg per mL Oral > Solid: 0.5 mg; 1 mg	Chronic hepatitis B

Eravacycline

Section	Indications
Reserve group antibiotics Parenteral > General injections > IV: 50 mg lyophilized powder for injection	Carbapenem resistant Enterobacteriales

Erythromycin

Section	Indications
<p>Watch group antibiotics</p> <p>Parenteral > General injections > IV: 500 mg in vial powder for injection (as lactobionate)</p> <p>Oral > Liquid: 125 mg per 5 mL (as stearate or ethylsuccinate)</p> <p>Oral > Solid: 250 mg (as stearate or ethylsuccinate)</p>	<p>Second choix</p> <p>Therapeutic equivalent to clarithromycin pour</p> <p>Acute pharyngitis</p> <p>Autres indications</p> <p>Bacterial infection of unspecified site</p>

Ethambutol

Section	Indications
<p>Antituberculosis medicines</p> <p>Parenteral > General injections > IV: 1000 mg per 10 mL; 2000 mg per 20 mL</p> <p>Oral > Solid > dispersible tablet: 100 mg</p> <p>Oral > Solid > tablet: 100 mg (hydrochloride); 400 mg (hydrochloride)</p>	<p>Other specified tuberculosis</p> <p>Tuberculosis</p>

Ethambutol + isoniazid

Section	Indications
<p>Antituberculosis medicines</p> <p>Oral > Solid: 400 mg + 150 mg tablet</p>	<p>Tuberculosis</p>

Ethambutol + isoniazid + pyrazinamide + rifampicin

Section	Indications
<p>Antituberculosis medicines</p> <p>Oral > Solid: 275 mg + 75 mg + 400 mg + 150 mg tablet</p>	<p>Tuberculosis</p>

Ethambutol + isoniazid + rifampicin

Section	Indications
<p>Antituberculosis medicines</p> <p>Oral > Solid: 275 mg + 75 mg + 150 mg tablet</p>	<p>Tuberculosis</p>

Ethionamide

Section	Indications
<p>Antituberculosis medicines</p> <p>Oral > Solid > dispersible tablet: 125 mg</p> <p>Oral > Solid > tablet: 250 mg</p>	<p>Multi-drug resistant Mycobacterium tuberculosis</p> <p>Tuberculous meningitis</p>

Fexinidazole

Section	Indications
Medicines for the treatment of 1st stage African trypanosomiasis Oral > Solid: 600 mg	African trypanosomiasis
Medicines for the treatment of 2nd stage African trypanosomiasis Oral > Solid: 600 mg	African trypanosomiasis

Fifth generation cephalosporins

Section	Indications
Reserve group antibiotics	Other specified bacterial diseases

Flomoxef

Section	Indications
Watch group antibiotics Parenteral > General injections > IV: 0.5 g in vial powder for injection; 1 g in vial powder for injection	Other specified other antibiotic resistant Enterobacteriales

Fluconazole

Section	Indications
Antifungal medicines	Cryptococcosis
Parenteral > General injections > IV: 2 mg per mL in vial	Candidosis
Oral > Liquid: 50 mg per 5 mL; 50 mg per 5 mL powder for oral liquid	
Oral > Solid > capsule: 50 mg	

Flucytosine

Section	Indications
Antifungal medicines	Cryptococcosis
Parenteral > General injections > IV: 2.5 g per 250 mL infusion	
Oral > Solid: 250 mg capsule	

Fosfomycin (injection)

Section	Indications
Reserve group antibiotics Parenteral > General injections > IV: 2 g in vial (as sodium) powder for injection; 4 g in vial (as sodium) powder for injection	Other specified bacterial diseases Carbapenem resistant Acinetobacter baumannii Carbapenem-resistant Pseudomonas aeruginosa Carbapenem resistant Enterobacterales

Fourth generation cephalosporins

Section	Indications
Watch group antibiotics	Other specified bacterial diseases

Gatifloxacin

Section	Indications
Antituberculosis medicines Oral > Solid: 200 mg; 400 mg	Multi-drug resistant Mycobacterium tuberculosis

Gentamicin

Section	Indications
Access group antibiotics	Premier choix
Parenteral > General injections > unspecified: 10 mg per mL in 2 mL vial (as sulfate); 40 mg per mL in 2 mL vial (as sulfate)	<p>Neonatal meningitis co-prescrite avec amoxicillin</p> <p>Sepsis without septic shock co-prescrite avec amoxicillin</p> <p>Bacterial pneumonia (Community-acquired pneumonia - severe) [children] co-prescrite avec ampicilllin</p> <p>Bacterial pneumonia (Community-acquired pneumonia - severe) [children] co-prescrite avec ampicillin</p> <p>Sepsis without septic shock co-prescrite avec ampicillin</p> <p>Acute malnutrition in infants, children or adolescents (complicated) [children] co-prescrite avec ampicillin</p> <p>Peritoneal abscess (severe) co-prescrite avec ampicillin</p> <p>Peritonitis (mild-moderate) co-prescrite avec ampicillin</p> <p>Peritonitis (severe) co-prescrite avec ampicillin</p> <p>Peritoneal abscess (mild-moderate) co-prescrite avec benzylpenicilllin</p> <p>Bacterial pneumonia (Community-acquired pneumonia - severe) [children] co-prescrite avec benzylpenicilllin</p> <p>Acute malnutrition in infants, children or adolescents (complicated) [children] co-prescrite avec benzylpenicilllin</p> <p>Sepsis without septic shock Second choix</p>
	<p>Other specified prophylactic measures</p> <p>Gonococcal infection</p>
	Autres indications
	<p>Bacterial infection of unspecified site</p>

Glecaprevir + pibrentasvir

Section	Indications
Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations	Chronic hepatitis C
Oral > Solid: 50 mg + 20 mg granules	
Oral > Solid > tablet: 100 mg + 40 mg	

Griseofulvin

Section	Indications
Antifungal medicines	Dermatophytosis
Oral > Liquid: 125 mg per 5 mL	
Oral > Solid: 125 mg; 250 mg	

Hydroxychloroquine

Section	Indications
Antimalarial medicines > For chemoprevention	Therapeutic equivalent to chloroquine pour Malaria due to Plasmodium falciparum

Imipenem + cilastatin

Section	Indications
Watch group antibiotics	Second choix Therapeutic equivalent to meropenem pour Neutropenia (high-risk)
Parenteral > General injections > IV: 250 mg (as monohydrate) + 250 mg (as sodium salt) powder for injection; 500 mg (as monohydrate) + 500 mg (as sodium salt) powder for injection	Therapeutic equivalent to meropenem pour Peritoneal abscess (severe) Therapeutic equivalent to meropenem pour Peritonitis (severe)
	Autres indications
	Pseudomonas aeruginosa resistant to other antibiotic Antibiotic resistant Acinetobacter baumannii
Antituberculosis medicines	Therapeutic equivalent to meropenem pour Multi-drug resistant Mycobacterium tuberculosis

Imipenem + cilastatin + relebactam

Section	Indications
Reserve group antibiotics Parenteral > General injections > IV: 500 mg + 500 mg + 250 mg powder for injection	Other specified other antibiotic resistant Enterobacteriales Carbapenem resistant Enterobacteriales Carbapenem-resistant Pseudomonas aeruginosa

Indinavir

Section	Indications
Antiretrovirals > Protease inhibitors Oral > Solid: 400 mg (as sulfate)	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Isoniazid

Section	Indications
Antituberculosis medicines Parenteral > General injections > IV: 100 mg per mL Oral > Solid > dispersible tablet: 100 mg Oral > Solid > tablet: 100 mg; 300 mg	Other specified tuberculosis Tuberculosis

Isoniazid + pyrazinamide + rifampicin

Section	Indications
Antituberculosis medicines Oral > Solid > dispersible tablet: 50 mg + 150 mg + 75 mg	Tuberculosis

Isoniazid + pyridoxine + sulfamethoxazole + trimethoprim

Section	Indications
Medicines for prevention of HIV-related opportunistic infections Oral > Solid: 300 mg + 25 mg + 800 mg + 160 mg tablet (scored)	Other specified prophylactic measures

Isoniazid + rifampicin

Section	Indications
Antituberculosis medicines Oral > Solid > dispersible tablet: 50 mg + 75 mg Oral > Solid > tablet: 75 mg + 150 mg; 150 mg + 300 mg	Tuberculosis

Isoniazid + rifapentine

Section	Indications
Antituberculosis medicines Oral > Solid: 300 mg + 300 mg tablet (scored)	Latent tuberculosis

Itraconazole

Section	Indications
Antifungal medicines Oral > Liquid: 10 mg per mL Oral > Solid: 100 mg	Chronic pulmonary aspergillosis Chromoblastomycosis Histoplasmosis Talaromycosis Sporotrichosis Paracoccidioidomycosis

Ivermectin

Section	Indications
Intestinal anthelmintics Oral > Solid > tablet: 3 mg	Strongyloidiasis Ascariasis Trichuriasis Hookworm diseases Ancylostomiasis
Antifilarials Oral > Solid > tablet: 3 mg	Onchocerciasis Lymphatic filariasis
Medicines for ectoparasitic infections Oral > Solid > tablet: 3 mg	Scabies

Kanamycin (injection)

Section	Indications
Antituberculosis medicines Parenteral > General injections > IV: 1000 mg powder for injection (vial)	Multi-drug resistant Mycobacterium tuberculosis

Lamivudine

Section	Indications
Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors Oral > Liquid: 50 mg per 5 mL Oral > Solid: 150 mg tablet	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Lamivudine + nevirapine + zidovudine

Section	Indications
Fixed-dose combinations of antiretrovirals Oral > Solid: 30 mg + 50 mg + 60 mg Tablet; 150 mg + 200 mg + 300 mg Tablet	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Lamivudine + tenofovir

Section	Indications
Fixed-dose combinations of antiretrovirals	Therapeutic equivalent to emtricitabine + tenofovir pour
	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
	Therapeutic equivalent to emtricitabine + tenofovir pour
	Contact with or exposure to human immunodeficiency virus

Lamivudine + zidovudine

Section	Indications
Fixed-dose combinations of antiretrovirals Oral > Solid: 30 mg + 60 mg Tablet; 150 mg + 300 mg Tablet	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Ledipasvir + sofosbuvir

Section	Indications
Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations Oral > Solid: 90 mg + 400 mg tablet	Chronic hepatitis C

Levamisole

Section	Indications
Intestinal anthelmintics Oral > Solid > tablet: 50 mg (as hydrochloride); 150 mg (as hydrochloride)	Ascariasis

Levofloxacin

Section

Antituberculosis medicines

Oral > Solid > dispersible tablet: 100 mg

Oral > Solid > tablet: 250 mg; 500 mg; 750 mg

Indications

Multi-drug resistant *Mycobacterium tuberculosis*

Linezolid

Section

Reserve group antibiotics

Parenteral > General injections > IV: 2 mg per mL in 300 mL bag

Oral > Liquid: 100 mg per 5 mL powder for oral liquid

Oral > Solid: 400 mg tablet; 600 mg tablet

Oral > Solid > dispersible tablet: 150 mg

Oral > Solid > tablet: 600 mg

Indications

Other specified bacterial diseases

Methicillin resistant *Staphylococcus aureus*

Vancomycin resistant *Staphylococcus aureus*

Vancomycin resistant *Enterococcus*

Multi-drug resistant *Mycobacterium tuberculosis*

Lopinavir + ritonavir

Section

Antiretrovirals > Protease inhibitors

Oral > Solid > tablet: 100 mg + 25 mg tablet (heat-stable); 200 mg + 50 mg tablet (heat-stable)

Oral > Solid > dosage form: 40 mg + 10 mg

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Mebendazole

Section

Intestinal anthelmintics

Oral > Solid > tablet: 100 mg (chewable); 500 mg (chewable)

Indications

Ascariasis

Enterobiasis

Trichuriasis

Hookworm diseases

Other specified echinococcosis

Cysticidal medicines

Oral > Solid > tablet: 100 mg (chewable); 500 mg (chewable)

Mefloquine

Section	Indications
Antimalarial medicines > For curative treatment Oral > Solid: 250 mg tablet (hydrochloride)	Malaria due to <i>Plasmodium falciparum</i> Malaria due to <i>Plasmodium vivax</i>
Antimalarial medicines > For chemoprevention Oral > Solid: 250 mg tablet (hydrochloride)	Malaria due to <i>Plasmodium falciparum</i>

Meglumine antimoniate

Section	Indications
Antileishmaniasis medicines Parenteral > General injections > IM: 1.5 g per 5 mL in 5 mL ampoule	Visceral leishmaniasis Cutaneous leishmaniasis Mucocutaneous leishmaniasis

Melarsoprol

Section	Indications
Medicines for the treatment of 2nd stage African trypanosomiasis Parenteral > General injections > IV: 3.6% in 5 mL ampoule solution (180 mg of active compound)	African trypanosomiasis

Meropenem

Section	Indications
Watch group antibiotics Parenteral > General injections > IV: 500 mg in vial (as trihydrate) powder for injection; 1 g in vial (as trihydrate) powder for injection	Second choix Neutropenia (high-risk) Peritoneal abscess (severe) Peritonitis (severe) Neonatal meningitis
Antituberculosis medicines Parenteral > General injections > IV: 500 mg in vial (as trihydrate) powder for injection; 1 g in vial (as trihydrate) powder for injection	Multi-drug resistant <i>Mycobacterium tuberculosis</i>

Meropenem + vaborbactam

Section	Indications
Reserve group antibiotics Parenteral > General injections > IV: 1 g in vial + 1 g in vial powder for injection	Carbapenem-resistant <i>Pseudomonas aeruginosa</i> Carbapenem resistant <i>Enterobacteriales</i> Carbapenem resistant <i>Acinetobacter baumannii</i>

Metronidazole

Section	Indications
<p>Access group antibiotics</p> <p>Oral > Liquid: 200 mg per 5 mL (as benzoate)</p> <p>Oral > Solid: 200 to 500 mg tablet</p> <p>Parenteral > General injections > unspecified: 500 mg per 100 mL in vial Injection</p> <p>Local > Rectal > Suppository: 500 mg; 1 g</p> <p>Parenteral > General injections > unspecified: 500 mg per 100 mL in vial</p> <p>Oral > Solid > tablet: 200 mg; 250 mg; 400 mg; 500 mg</p>	<p>Premier choix</p> <p>Intestinal infections due to <i>Clostridioides difficile</i></p> <p>Trichomoniasis</p> <p>co-prescrite avec cefazolin</p> <p>Other specified prophylactic measures</p> <p>co-prescrite avec cefotaxime</p> <p>Peritonitis (severe)</p> <p>co-prescrite avec cefotaxime</p> <p>Peritonitis (mild-moderate)</p> <p>co-prescrite avec cefotaxime</p> <p>Peritoneal abscess (mild-moderate)</p> <p>co-prescrite avec cefotaxime</p> <p>Peritoneal abscess (severe)</p> <p>co-prescrite avec ceftriaxone</p> <p>Necrotising fasciitis</p> <p>co-prescrite avec ceftriaxone</p> <p>Peritonitis (severe)</p> <p>co-prescrite avec ceftriaxone</p> <p>Peritoneal abscess (mild-moderate)</p> <p>co-prescrite avec ceftriaxone</p> <p>Peritoneal abscess (severe)</p> <p>co-prescrite avec ceftriaxone</p> <p>Peritonitis (mild-moderate)</p> <p>Second choix</p> <p>co-prescrite avec ciprofloxacin</p> <p>Peritonitis (mild-moderate)</p> <p>co-prescrite avec ciprofloxacin</p> <p>Peritoneal abscess (mild-moderate)</p> <p>Autres indications</p> <p>Bacterial infection of unspecified site</p> <p>Amoebiasis</p>
<p>Antiamoebic and antigiardiasis medicines</p> <p>Oral > Liquid: 200 mg per 5 mL (as benzoate)</p> <p>Parenteral > General injections > unspecified: 500 mg in 100 mL vial</p> <p>Oral > Solid > tablet: 200 mg; 250 mg; 400 mg; 500 mg</p>	

Micafungin

Section	Indications
Antifungal medicines Parenteral > General injections > IV: 50 mg in vial (as sodium) powder for injection; 100 mg in vial (as sodium) powder for injection	Systemic or invasive candidosis

Miltefosine

Section	Indications
Antileishmaniasis medicines Oral > Solid: 10 mg; 50 mg	Visceral leishmaniasis Mucocutaneous leishmaniasis Cutaneous leishmaniasis

Moxifloxacin

Section	Indications
Antituberculosis medicines Oral > Solid > dispersible tablet: 100 mg Oral > Solid > tablet: 400 mg	Multi-drug resistant Mycobacterium tuberculosis Tuberculosis

Nalidixic acid

Section	Indications
Anti-infective medicines Oral > Solid: 250 mg; 500 mg	Shigella resistant to unspecified antibiotic

Nelfinavir

Section	Indications
Antiretrovirals > Protease inhibitors Oral > Solid: 250 mg (as mesilate) Oral > Other: 50 mg per g oral powder	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Nevirapine

Section	Indications
Antiretrovirals > Non-nucleoside reverse transcriptase inhibitors Oral > Liquid: 50 mg per 5 mL Oral > Solid > dispersible tablet: 50 mg Oral > Solid > tablet: 200 mg	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Niclosamide

Section	Indications
Intestinal anthelmintics Oral > Solid: 500 mg tablet (chewable)	Hymenolepiasis Diphyllobothriasis Taeniasis due to <i>Taenia saginata</i> Taeniasis due to <i>Taenia solium</i>

Nifurtimox

Section	Indications
American trypanosomiasis Oral > Solid > tablet: 30 mg (scored); 120 mg (scored)	Chagas disease
Medicines for the treatment of 2nd stage African trypanosomiasis Oral > Solid > tablet: 30 mg (scored); 120 mg (scored)	African trypanosomiasis

Nitrofurantoin

Section	Indications
Access group antibiotics Oral > Liquid: 25 mg per 5 mL oral liquid Oral > Solid > dosage form: 100 mg; 50 mg	Premier choix Infectious cystitis

Nystatin

Section	Indications
Antifungal medicines Oral > Liquid: 100000 IU per mL Local > Topical > Other: 100000 IU pessary Oral > Solid > dosage form: 500000 IU Oral > Solid > lozenge: 100000 IU	Candidosis

Ofloxacin

Section	Indications
Antituberculosis medicines Oral > Solid: 200 mg; 400 mg	Multi-drug resistant <i>Mycobacterium tuberculosis</i>

Omadacycline

Section	Indications
Reserve group antibiotics	Methicillin resistant <i>Staphylococcus aureus</i>
Parenteral > General injections > IV: 100 mg lyophilized powder for injection	
Oral > Solid: 300 mg	

Ombitasvir + paritaprevir + ritonavir

Section	Indications
Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations	Chronic hepatitis C
Oral > Solid: 12.5 mg + 75 mg + 50 mg tablet	

Oseltamivir

Section	Indications
Other antivirals	Influenza due to identified seasonal influenza virus
Oral > Solid: 30 mg capsule (as phosphate); 45 mg capsule (as phosphate); 75 mg capsule (as phosphate)	

Oxamniquine

Section	Indications
Antischistosomals and other antitrematode medicines	Schistosomiasis due to <i>Schistosoma mansoni</i>
Oral > Liquid: 250 mg per 5 mL	
Oral > Solid > capsule: 250 mg	

Oxazolidinones

Section	Indications
Reserve group antibiotics	Other specified bacterial diseases
.	

P-aminosalicylate sodium

Section	Indications
Antituberculosis medicines	Multi-drug resistant <i>Mycobacterium tuberculosis</i>
Oral > Liquid: 5.52 g in sachet (equivalent to 4 g p-aminosalicylic acid) powder for oral solution	

P-aminosalicylic acid

Section	Indications
Antituberculosis medicines Oral > Solid: 4 g granules in sachet	Multi-drug resistant Mycobacterium tuberculosis

Paromomycin

Section	Indications
Antileishmaniasis medicines Parenteral > General injections > IM: 750 mg paromomycin base (as sulfate)	Visceral leishmaniasis
Antiamoebic and antigiardiasis medicines Oral > Liquid: 125 mg per 5 mL as sulfate Oral > Solid: 250 mg as sulfate	Amoebiasis

Pegylated interferon alfa (2a)

Section	Indications
Medicines for hepatitis C > Other antivirals for hepatitis C Parenteral > General injections > SC: 180 µg in vial; 180 µg in prefilled syringe	Chronic hepatitis C

Pegylated interferon alfa (2b)

Section	Indications
Medicines for hepatitis C > Other antivirals for hepatitis C Parenteral > General injections > SC: 80 µg in prefilled syringe; 100 µg in prefilled syringe	Chronic hepatitis C

Pentamidine

Section	Indications
Antileishmaniasis medicines Parenteral > General injections > IM: 200 mg (as isetionate); 300 mg (as isetionate)	Visceral leishmaniasis
Medicines for the treatment of 1st stage African trypanosomiasis Parenteral > General injections > IM: 300 mg in vial (as isetionate) powder for injection	African trypanosomiasis
Antipneumocystosis and antitoxoplasmosis medicines Oral > Solid > tablet: 200 mg (as isethionate); 300 mg (as isethionate)	Pneumocystosis

Phenoxymethylpenicillin

Section	Indications
Access group antibiotics	Premier choix
Oral > Liquid: 250 mg per 5 mL (as potassium salt) powder for oral liquid	Acute pharyngitis
Oral > Solid: 250 mg (as potassium salt) tablet	Periapical abscess without sinus
Oral > Solid: 250 mg (as potassium salt); 500 mg (as potassium salt)	Bacterial pneumonia (Community-acquired pneumonia - mild to moderate)
	Autres indications
	Bacterial infection of unspecified site

Piperacillin + tazobactam

Section	Indications
Watch group antibiotics	Premier choix
Parenteral > General injections > IV: 2 g (as sodium salt) + 250 mg (as sodium salt) powder for injection; 4 g (as sodium salt) + 500 mg (as sodium salt) powder for injection	Peritoneal abscess (severe)
	Other specified pneumonia (Hospital-acquired pneumonia)
	Neutropenia (high-risk)
	Peritonitis (severe)
	co-prescrite avec clindamycin
	Necrotising fasciitis

Plazomicin

Section	Indications
Reserve group antibiotics	Carbapenem resistant Acinetobacter baumannii
Parenteral > General injections > IV: 500 mg per 10 mL	Carbapenem-resistant Pseudomonas aeruginosa
	Carbapenem resistant Enterobacteriales

Polymyxin B (injection)

Section	Indications
Reserve group antibiotics	Carbapenem resistant Acinetobacter baumannii
Parenteral > General injections > IV: 500000 IU in vial powder for injection (equivalent to 50 mg polymyxin B base)	Carbapenem-resistant Pseudomonas aeruginosa
	Carbapenem resistant Enterobacteriales

Polymyxins

Section	Indications
Reserve group antibiotics	Other specified bacterial diseases

Potassium iodide

Section	Indications
Antifungal medicines Local > Topical > Solution: Saturated solution	Sporotrichosis

Praziquantel

Section	Indications
Antischistosomals and other antitrematode medicines Oral > Solid > tablet: 600 mg (scored); 500 mg; 150 mg	Paragonimiasis Clonorchiasis Opisthorchiasis Schistosomiasis
Intestinal anthelmintics Oral > Solid > tablet: 600 mg (scored); 500 mg; 150 mg	Taeniasis due to <i>Taenia saginata</i> Taeniasis due to <i>Taenia solium</i> Hymenolepiasis Diphyllobothriasis
Cysticidal medicines Oral > Solid > tablet: 600 mg (scored); 500 mg; 150 mg	Cysticercosis of central nervous system

Pretomanid

Section	Indications
Antituberculosis medicines Oral > Solid > tablet: 200 mg	Multi-drug resistant <i>Mycobacterium tuberculosis</i>

Primaquine

Section	Indications
Antimalarial medicines > For curative treatment Oral > Solid: 7.5 mg tablet (as phosphate); 15 mg tablet (as phosphate)	Malaria due to <i>Plasmodium ovale</i> Malaria due to <i>Plasmodium vivax</i>

Procaine benzylpenicillin

Section	Indications
Access group antibiotics Parenteral > General injections > IM: 1 g in vial (=1 million IU) powder for injection; 3 g in vial (=3 million IU) powder for injection	Premier choix Congenital syphilis [children] Second choix Syphilis

Proguanil

Section	Indications
Antimalarial medicines > For chemoprevention Oral > Solid: 100 mg tablet (hydrochloride)	Malaria due to Plasmodium falciparum

Protonamide

Section	Indications
Antituberculosis medicines	Therapeutic equivalent to ethionamide pour Multi-drug resistant Mycobacterium tuberculosis

Pyrantel

Section	Indications
Intestinal anthelmintics Oral > Solid > tablet: 250 mg (chewable) (as embonate or pamoate)	Ascariasis Trichuriasis Enterobiasis Hookworm diseases

Pyrazinamide

Section	Indications
Antituberculosis medicines Oral > Solid > dispersible tablet: 150 mg Oral > Solid > tablet: 400 mg; 500 mg	Tuberculosis

Pyrimethamine

Section	Indications
Antipneumocystosis and antitoxoplasmosis medicines Oral > Solid: 25 mg	Toxoplasmosis

Quinine

Section	Indications
Antimalarial medicines > For curative treatment Parenteral > General injections > IV: 300 mg per mL in 2 mL ampoule (quinine hydrochloride) Oral > Solid: 300 mg (quinine sulfate or quinine bisulfate)	Malaria due to <i>Plasmodium falciparum</i>

Raltegravir

Section	Indications
Antiretrovirals > Integrase inhibitors Oral > Liquid: 100 mg granules for oral suspension Oral > Solid: 400 mg tablet; 25 mg tablet (chewable)	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Ravidasvir

Section	Indications
Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations Oral > Solid > tablet: 200 mg	Chronic hepatitis C

Ribavirin

Section	Indications
Other antivirals Parenteral > General injections > IV: 1000 mg per 10 mL phosphate buffer solution; 800 mg per 10 mL phosphate buffer solution Oral > Solid: 200 mg; 400 mg; 600 mg	Viral haemorrhagic fever, not elsewhere classified
Medicines for hepatitis C > Other antivirals for hepatitis C Parenteral > General injections > IV: 1000 mg per 10 mL phosphate buffer solution; 800 mg per 10 mL phosphate buffer solution Oral > Solid: 200 mg; 400 mg; 600 mg	Chronic hepatitis C

Rifabutin

Section	Indications
Antituberculosis medicines Oral > Solid: 150 mg	Tuberculosis

Rifampicin

Section	Indications
Antituberculosis medicines	Tuberculosis
Oral > Liquid: 20 mg per mL	Other specified tuberculosis
Oral > Solid: 150 mg; 300 mg	
PARENTERAL > General injections > IV: 600 mg in vial powder for injection	
Antileprosy medicines	Leprosy
Oral > Liquid: 20 mg per mL	
Oral > Solid: 150 mg; 300 mg	

Rifapentine

Section	Indications
Antituberculosis medicines	Tuberculosis
Oral > Solid > tablet: 150 mg; 300 mg	Latent tuberculosis

Ritonavir

Section	Indications
Antiretrovirals > Protease inhibitors	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
Oral > Solid: 25 mg tablet (heat stable); 100 mg tablet (heat stable)	

Saquinavir

Section	Indications
Antiretrovirals > Protease inhibitors	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
Oral > Solid: 200 mg; 500 mg	

Simeprevir

Section	Indications
Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations	Chronic hepatitis C
Oral > Solid: 150 mg	

Sodium stibogluconate

Section	Indications
Antileishmaniasis medicines Parenteral > General injections > unspecified: 100 mg per mL in 30 mL vial	Visceral leishmaniasis Mucocutaneous leishmaniasis Cutaneous leishmaniasis

Sofosbuvir

Section	Indications
Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations Oral > Solid > tablet: 200 mg; 400 mg	Chronic hepatitis C

Sofosbuvir + velpatasvir

Section	Indications
Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations Oral > Solid > tablet: 200 mg + 50 mg; 400 mg + 100 mg	Chronic hepatitis C

Spectinomycin

Section	Indications
Access group antibiotics Parenteral > General injections > unspecified: 2 g in vial (as hydrochloride) powder for injection	Second choix Gonococcal infection
	Autres indications
	Bacterial infection of unspecified site

Stavudine

Section	Indications
Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors Oral > Liquid: 5 mg per 5 mL powder for oral solution Oral > Solid: 15 mg; 20 mg; 30 mg	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Streptomycin (injection)

Section	Indications
Antituberculosis medicines Parenteral > General injections > IV: 1 g powder for injection (as sulfate) as vial	Multi-drug resistant Mycobacterium tuberculosis

Sulfadiazine

Section	Indications
Antipneumocystosis and antitoxoplasmosis medicines Oral > Solid: 500 mg	Toxoplasmosis
Anti-infective medicines Oral > Solid: 500 mg Parenteral > General injections > unspecified: 250 mg in 4 mL ampoule (sodium salt)	Bacterial infection of unspecified site

Sulfadimidine

Section	Indications
Anti-infective medicines Oral > Liquid: 500 mg per 5 mL	Bacterial infection of unspecified site
Oral > Solid: 500 mg Parenteral > General injections > unspecified: 1 g in 3 mL ampoule (sodium salt)	

Sulfadoxine + pyrimethamine

Section	Indications
Antimalarial medicines > For curative treatment Oral > Solid: 500 mg + 25 mg tablet	Malaria due to Plasmodium falciparum Malaria due to Plasmodium vivax
Antimalarial medicines > For chemoprevention Oral > Solid: 500 mg + 25 mg tablet	Malaria due to Plasmodium falciparum
Oral > Solid: 250 mg + 12.5 mg tablet	Malaria

Sulfamethoxazole + trimethoprim

Section	Indications
Access group antibiotics Parenteral > General injections > IV: 80 mg + 16 mg per mL in 10 mL ampoule; 80 mg + 16 mg per mL in 5 mL ampoule Oral > Liquid: 200 mg + 40 mg per 5 mL oral liquid Oral > Solid: 100 mg + 20 mg tablet; 400 mg + 80 mg tablet; 800 mg + 160 mg tablet Oral > Solid > dispersible tablet: 100 mg + 20 mg	Premier choix Infectious cystitis Second choix Infectious gastroenteritis or colitis without specification of infectious agent Autres indications Bacterial infection of unspecified site Pneumocystosis
Antipneumocystosis and antitoxoplasmosis medicines Parenteral > General injections > IV: 80 mg + 16 mg per mL in 5 mL ampoule; 80 mg + 16 mg per mL in 10 mL ampoule Oral > Liquid: 200 mg + 40 mg per 5 mL oral liquid Oral > Solid: 100 mg + 20 mg tablet; 400 mg + 80 mg tablet; 800 mg + 160 mg tablet Oral > Solid > dispersible tablet: 100 mg + 20 mg	

Suramin sodium

Section	Indications
Antifilarials Parenteral > General injections > IV: 1 g in vial	Filariasis
Medicines for the treatment of 1st stage African trypanosomiasis Parenteral > General injections > IV: 1 g in vial	African trypanosomiasis

Tedizolid

Section	Indications
Reserve group antibiotics	Therapeutic equivalent to linezolid pour Methicillin resistant Staphylococcus aureus
	Therapeutic equivalent to linezolid pour Vancomycin resistant Staphylococcus aureus
	Therapeutic equivalent to linezolid pour Vancomycin resistant Enterococcus

Tenofovir alafenamide

Section	Indications
Medicines for hepatitis B > Nucleoside/Nucleotide reverse transcriptase inhibitors Oral > Solid: 25 mg	Chronic hepatitis B

Tenofovir disoproxil fumarate

Section	Indications
Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors Oral > Solid: 300 mg tablet (equivalent to 245 mg tenofovir disoproxil)	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
	Contact with or exposure to human immunodeficiency virus
Medicines for hepatitis B > Nucleoside/Nucleotide reverse transcriptase inhibitors Oral > Solid: 300 mg tablet (equivalent to 245 mg tenofovir disoproxil)	Chronic hepatitis B

Terizidone

Section	Indications
Antituberculosis medicines	Therapeutic equivalent to cycloserine pour Multi-drug resistant <i>Mycobacterium tuberculosis</i>

Tetracycline

Section	Indications
Access group antibiotics Oral > Solid: 250 mg (hydrochloride)	Bacterial infection of unspecified site

Tigecycline

Section	Indications
Reserve group antibiotics Parenteral > General injections > IV: 50 mg in vial powder for injection	Other specified bacterial diseases

Tinidazole

Section	Indications
Antiamoebic and antigiardiasis medicines	Therapeutic equivalent to metronidazole pour Amoebiasis

Triclabendazole

Section	Indications
Antischistosomals and other antitrematode medicines Oral > Solid > tablet: 250 mg (scored)	Paragonimiasis Fascioliasis

Trimethoprim

Section	Indications
Access group antibiotics Oral > Liquid: 50 mg per mL Oral > Solid: 100 mg; 200 mg	Premier choix Infectious cystitis

Valaciclovir

Section	Indications
Antiherpes medicines	Therapeutic equivalent to aciclovir pour Zoster
	Therapeutic equivalent to aciclovir pour Varicella
	Therapeutic equivalent to aciclovir pour Herpes simplex infections

Valganciclovir

Section	Indications
Other antivirals Oral > Liquid: 50 mg per mL powder for oral solution Oral > Solid > tablet: 450 mg	Cytomegaloviral retinitis

Vancomycin

Section	Indications
<p>Watch group antibiotics</p> <p>Parenteral > General injections > IV: 250 mg in vial (as hydrochloride) powder for injection</p> <p>Oral > Solid > capsule: 125 mg (as hydrochloride); 250 mg (as hydrochloride)</p> <p>Parenteral > General injections > IV: 250 mg in vial (as hydrochloride) powder for injection; 500 mg in vial (as hydrochloride) powder for injection; 1 g in vial (as hydrochloride) powder for injection</p> <p>Parenteral > Locoregional injections > Intravitreal: 250 mg in vial (as hydrochloride) powder for injection; 500 mg in vial (as hydrochloride) powder for injection; 1 g in vial (as hydrochloride) powder for injection</p>	<p>Premier choix</p> <p>Necrotising fasciitis co-prescrite avec ceftazidime</p> <p>Endophthalmitis co-prescrite avec ceftriaxone</p> <p>Endophthalmitis</p> <p>Second choix</p> <p>Neutropenia (high-risk)</p> <p>Intestinal infections due to Clostridioides difficile</p> <p>Autres indications</p> <p>Methicillin resistant Staphylococcus aureus</p>

Voriconazole

Section	Indications
<p>Antifungal medicines</p> <p>Parenteral > General injections > IV: 200 mg in vial powder for injection</p> <p>Oral > Liquid: 40 mg per mL powder for oral liquid</p> <p>Oral > Solid: 50 mg tablet; 200 mg tablet</p>	<p>Chronic pulmonary aspergillosis</p> <p>Invasive aspergillosis</p>

Zidovudine

Section	Indications
<p>Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors</p> <p>Parenteral > General injections > IV: 10 mg per mL in 20 mL vial solution for IV infusion</p> <p>Oral > Liquid: 50 mg per 5 mL</p> <p>Oral > Solid > tablet: 300 mg</p> <p>Oral > Solid > capsule: 250 mg</p>	<p>Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified</p>